Alkermes plc - Ordinary Shares (NQ:ALKS)

41.75 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 17, 2023

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

August 10, 2023

Biotech is still booming, if you pick the right biotech stocks.

Via The Motley Fool

Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega ↗

July 26, 2023

Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56

Via Benzinga

Earnings Preview: Alkermes ↗

July 25, 2023

Via Benzinga

Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor

June 28, 2023

From Sarissa Capital Management LP

Via Business Wire

Where Alkermes Stands With Analysts ↗

June 07, 2023

Via Benzinga

Alkermes Earnings Perspective: Return On Capital Employed ↗

April 27, 2023

Via Benzinga

Analyst Expectations for Alkermes's Future ↗

April 27, 2023

Via Benzinga

The Latest Analyst Ratings for Alkermes ↗

April 27, 2023

Via Benzinga

A Preview Of Alkermes's Earnings ↗

April 25, 2023

Via Benzinga

Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders

June 26, 2023

From Sarissa Capital Management LP

Via Business Wire

Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board

June 22, 2023

From Sarissa Capital Management LP

Via Business Wire

Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board

June 20, 2023

From Sarissa Capital Management LP

Via Business Wire

Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board

June 15, 2023

From Sarissa Capital Management LP

Via Business Wire

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Alkermes Earnings Preview ↗

February 15, 2023

Via Benzinga

Analyst Ratings for Alkermes ↗

December 06, 2022

Via Benzinga

Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance ↗

November 02, 2022

Via Benzinga

Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes

June 13, 2023

From Sarissa Capital Management LP

Via Business Wire

Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board

June 09, 2023

From Sarissa Capital Management LP

Via Business Wire

Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements ↗

June 06, 2023

Via Benzinga

Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders

June 05, 2023

From Sarissa Capital Management LP

Via Business Wire

Alkermes Stock Sees Rising Relative Strength Rating ↗

March 28, 2023

The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.

Via Investor's Business Daily

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Alkermes: Commercialization Program On Track, Sales Coming In Strong ↗

March 04, 2023

The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance.

Via Talk Markets

Alkermes Stock Sees Rising Relative Price Strength ↗

February 17, 2023

The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.

Via Investor's Business Daily

Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗

February 16, 2023

Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.

Via Investor's Business Daily

Alkermes's Return On Capital Employed Insights ↗

November 10, 2022

Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022 ↗

November 03, 2022

Upgrades

Via Benzinga

Recap: Alkermes Q3 Earnings ↗

November 02, 2022

Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.